Home›Treatments›Allergy›Levocetirizine

Levocetirizine Tablets

Levocetirizine is an effective prescription-only antihistamine used to relieve symptoms of allergic conditions including hay fever (allergic rhinitis) and chronic hives (urticaria). As the active enantiomer of cetirizine, levocetirizine works by blocking histamine H1 receptors with high specificity, providing rapid relief from itching, sneezing, runny nose, and watery eyes. Suitable for adults and children aged 6 years and above, this once-daily medication offers 24-hour symptom control with minimal drowsiness in most patients when taken at the recommended dose.
Complete a short online consultation so our prescriber can confirm the treatment suits you.
The decision to supply the specific treatment and quantity requested will be based on whether our medical team are satisfied that it will be safe, appropriate, and effective.
Or 3 interest-free payments of £6.00 via Klarna
Tracked 24 Delivery3 interest-free payments via KlarnaDiscreet packaging

Levocetirizine Treatment

Product NameLevocetirizine
ManufacturerGlenmark Pharmaceuticals Europe Limited
Active IngredientLevocetirizine dihydrochloride
AdministrationOral
PresentationFilm-coated tablets
Available Strengths5mg / 30 Tablets
Product TypePOM — Prescription Only
Suitable for pregnancy?Consult doctor
Use with alcoholUse caution
Link to Patient Information LeafletLevocetirizine PIL ↗
Authored byNabeel

Medical Content Officer

Nabeel is a co-founder, and medical content officer of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.

Medical Doctor

Dr. Talal is a GMC registered doctor and medical content reviewer at Chemist Doctor. He ensures clinical accuracy and reliability across health content.

Approved byUsman

Medical Administrative Officer

Usman is a co-founder, and medical administrative officer of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical administration and operational priorities.

Review Date: 2 Jul 2026

Next Review: 1 Jan 2027

Published on: 19 Nov 2025

Last Updated: 3 Jul 2026